– USA, CA – Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced the election of Halley E. Gilbert to its board of directors.
“We are excited to welcome Halley Gilbert to Dermira’s board of directors,” said Tom Wiggans, chairman and chief executive officer of Dermira. “Dermira will benefit from Halley’s breadth of experience in building successful commercial biotechnology companies.”
About Halley Gilbert
Ms. Gilbert currently serves as senior vice president, corporate development and chief administrative officer of Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) overseeing corporate and business development, legal, compliance and government affairs. Ms. Gilbert has more than two decades of experience guiding biopharmaceutical companies through transformational change, as well as expertise in corporate transactions, governance and the operational and strategic issues relevant to launching new medicines. Prior to joining Ironwood, Ms. Gilbert was vice president, deputy general counsel at Cubist Pharmaceuticals, Inc., where she supported the launch of Cubist’s first acute care antibiotic, and prior to Cubist, she served as corporate counsel at Genzyme Corp. She began her career at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. Ms. Gilbert holds a J.D. from Northwestern University School of Law and a B.A. from Tufts University.
“I am excited to join the Dermira board at a time when the company continues to demonstrate its ability to successfully commercialize its first therapy and develop what might one day represent a best-in-disease therapy for chronic and debilitating skin disease,” said Halley Gilbert. “I look forward to sharing my experience to maximize opportunities and support the company’s mission to help patients living with chronic skin conditions.”
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify, develop and commercialize leading-edge medical dermatology products. The company’s approved treatment, QBREXZA cloth, is indicated for pediatric and adult patients with primary axillary hyperhidrosis. Please see the QBREXZA prescribing information. Dermira is evaluating lebrikizumab in Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis and has early-stage research and development programs in other areas of dermatology. Dermira is headquartered in Menlo Park, Calif.
For more information: https://www.dermira.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.